CD8A and melanoma: Given as monotherapy to mice bearing B16 melanomas, this agent did not seem to exhibit a significant anti-tumor effect, however, when combined with anti-CTLA-4 monoclonal antibody therapy, a synergistic enhancement in activated 41BB+ TRP2-specific CD8+ tumor-infiltrating lymphocytes were observed along with B16 tumor growth suppression.